American Century Companies Inc. Has $13.62 Million Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

American Century Companies Inc. raised its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 418.1% during the fourth quarter, Holdings Channel reports. The firm owned 862,365 shares of the company’s stock after buying an additional 695,932 shares during the period. American Century Companies Inc.’s holdings in Dr. Reddy’s Laboratories were worth $13,617,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of RDY. EverSource Wealth Advisors LLC increased its position in shares of Dr. Reddy’s Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after purchasing an additional 1,507 shares in the last quarter. POM Investment Strategies LLC grew its stake in Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after buying an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after buying an additional 2,093 shares in the last quarter. Glenmede Trust Co. NA bought a new position in shares of Dr. Reddy’s Laboratories in the third quarter valued at approximately $207,000. Finally, Sierra Ocean LLC bought a new stake in Dr. Reddy’s Laboratories during the 4th quarter worth approximately $43,000. 3.85% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on RDY shares. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Performance

RDY stock opened at $13.17 on Wednesday. The stock has a market capitalization of $10.99 billion, a PE ratio of 20.96 and a beta of 0.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a 50 day moving average price of $13.42 and a 200 day moving average price of $14.56. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $12.50 and a fifty-two week high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.